Amplia Therapeutics Ltd. (AU:ATX) has released an update.
Amplia Therapeutics Ltd. has announced a fully underwritten entitlement offer to raise $4.27 million by issuing new shares at a significant discount, aiming to fund the development of their lead cancer drug narmafotinib and support clinical trials. The offer has garnered robust backing from institutional investors and company directors, with funds intended for the ongoing ACCENT trial and further drug production for pancreatic and ovarian cancer treatments.
For further insights into AU:ATX stock, check out TipRanks’ Stock Analysis page.
